1. Home
  2. TMDX vs VCEL Comparison

TMDX vs VCEL Comparison

Compare TMDX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMDX
  • VCEL
  • Stock Information
  • Founded
  • TMDX 1998
  • VCEL 1989
  • Country
  • TMDX United States
  • VCEL United States
  • Employees
  • TMDX N/A
  • VCEL N/A
  • Industry
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TMDX Health Care
  • VCEL Health Care
  • Exchange
  • TMDX Nasdaq
  • VCEL Nasdaq
  • Market Cap
  • TMDX 2.3B
  • VCEL 2.1B
  • IPO Year
  • TMDX 2019
  • VCEL 1997
  • Fundamental
  • Price
  • TMDX $127.12
  • VCEL $41.30
  • Analyst Decision
  • TMDX Buy
  • VCEL Strong Buy
  • Analyst Count
  • TMDX 10
  • VCEL 8
  • Target Price
  • TMDX $122.89
  • VCEL $62.00
  • AVG Volume (30 Days)
  • TMDX 1.1M
  • VCEL 552.0K
  • Earning Date
  • TMDX 05-08-2025
  • VCEL 05-08-2025
  • Dividend Yield
  • TMDX N/A
  • VCEL N/A
  • EPS Growth
  • TMDX N/A
  • VCEL 521.85
  • EPS
  • TMDX 1.41
  • VCEL 0.05
  • Revenue
  • TMDX $488,227,000.00
  • VCEL $238,541,000.00
  • Revenue This Year
  • TMDX $32.58
  • VCEL $23.03
  • Revenue Next Year
  • TMDX $21.65
  • VCEL $24.52
  • P/E Ratio
  • TMDX $90.86
  • VCEL $693.44
  • Revenue Growth
  • TMDX 64.43
  • VCEL 14.80
  • 52 Week Low
  • TMDX $55.00
  • VCEL $37.39
  • 52 Week High
  • TMDX $177.37
  • VCEL $63.00
  • Technical
  • Relative Strength Index (RSI)
  • TMDX 76.52
  • VCEL 48.12
  • Support Level
  • TMDX $118.79
  • VCEL $40.38
  • Resistance Level
  • TMDX $130.48
  • VCEL $42.57
  • Average True Range (ATR)
  • TMDX 4.49
  • VCEL 1.69
  • MACD
  • TMDX -0.15
  • VCEL 0.06
  • Stochastic Oscillator
  • TMDX 83.53
  • VCEL 22.90

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: